Urokinase administration for intraventricular hemorrhage in adults: A retrospective analysis of hemorrhage volume reduction and clinical outcomes.
Journal
Journal of the Chinese Medical Association : JCMA
ISSN: 1728-7731
Titre abrégé: J Chin Med Assoc
Pays: Netherlands
ID NLM: 101174817
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
6
10
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Intraventricular hemorrhage (IVH) is a type of ventricular bleeding that results in significant morbidity and mortality. Multiple studies have investigated the use of urokinase in IVH treatment. The use of urokinase may lead to higher rates of hematoma resolution and lower mortality rates. However, further studies are required to determine efficacy of urokinase administration. This study examined the association between urokinase use, IVH volume reduction, and clinical outcomes. In total, 94 adult patients with hypertensive intracerebral hemorrhage with ventricular extension or primary IVH were enrolled between 2015 and 2021. Participants were categorized into two groups: "EVD combined with fibrinolysis" and "EVD only." The primary objective was to assess the reduction of IVH severity. Additionally, the study evaluated the functional outcomes and shunt dependency rate as secondary outcomes. Non-contrast computed tomography scans were obtained to measure the severity of IVH using the mGRAEB score. The main outcomes were the association among urokinase administration, reduced IVH severity, and functional outcomes. There were no significant differences in the reduction rate of mGRAEB scores within a 7-day period (-50.0 [-64.4 to -32.5] % vs -44.2 [-59.3 to -7.9] %; p = 0.489). In addition, investigation of the third and fourth ventricles showed similar findings between the two groups. Urokinase treatment was not associated with significant differences in the modified Rankin Scale (5.0 (4.0-5.0) vs. 4.5 (4.0-5.0), p = 0.674) or shunt dependency rate (33.3% vs 39.3%, p = 0.58). This study found that intraventricular urokinase use in patients with IVH was not associated with reduced IVH severity. In addition, urokinase use was not associated with better functional outcomes or minor shunt dependency rates.
Sections du résumé
BACKGROUND
Intraventricular hemorrhage (IVH) is a type of ventricular bleeding that results in significant morbidity and mortality. Multiple studies have investigated the use of urokinase in IVH treatment. The use of urokinase may lead to higher rates of hematoma resolution and lower mortality rates. However, further studies are required to determine efficacy of urokinase administration. This study examined the association between urokinase use, IVH volume reduction, and clinical outcomes.
METHODS
In total, 94 adult patients with hypertensive intracerebral hemorrhage with ventricular extension or primary IVH were enrolled between 2015 and 2021. Participants were categorized into two groups: "EVD combined with fibrinolysis" and "EVD only." The primary objective was to assess the reduction of IVH severity. Additionally, the study evaluated the functional outcomes and shunt dependency rate as secondary outcomes. Non-contrast computed tomography scans were obtained to measure the severity of IVH using the mGRAEB score. The main outcomes were the association among urokinase administration, reduced IVH severity, and functional outcomes.
RESULTS
There were no significant differences in the reduction rate of mGRAEB scores within a 7-day period (-50.0 [-64.4 to -32.5] % vs -44.2 [-59.3 to -7.9] %; p = 0.489). In addition, investigation of the third and fourth ventricles showed similar findings between the two groups. Urokinase treatment was not associated with significant differences in the modified Rankin Scale (5.0 (4.0-5.0) vs. 4.5 (4.0-5.0), p = 0.674) or shunt dependency rate (33.3% vs 39.3%, p = 0.58).
CONCLUSION
This study found that intraventricular urokinase use in patients with IVH was not associated with reduced IVH severity. In addition, urokinase use was not associated with better functional outcomes or minor shunt dependency rates.
Identifiants
pubmed: 37528523
doi: 10.1097/JCMA.0000000000000973
pii: 02118582-202310000-00011
doi:
Substances chimiques
Urokinase-Type Plasminogen Activator
EC 3.4.21.73
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
930-934Informations de copyright
Copyright © 2023, the Chinese Medical Association.
Déclaration de conflit d'intérêts
Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
Références
Hinson HE, Hanley DF, Ziai WC. Management of intraventricular hemorrhage. Curr Neurol Neurosci Rep 2010;10:73–82.
Hallevi H, Dar NS, Barreto AD, Morales MM, Martin-Schild S, Abraham AT, et al. The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications. Crit Care Med 2009;37:969–74, e1.
Flint AC, Roebken A, Singh V. Primary intraventricular hemorrhage: yield of diagnostic angiography and clinical outcome. Neurocrit Care 2008;8:330–6.
Pai A, Hegde A, Nair R, Menon G. Adult primary intraventricular hemorrhage: clinical characteristics and outcomes. J Neurosci Rural Pract 2020;11:623–8.
Barnaure I, Liberato AC, Gonzalez RG, Romero JM. Isolated intraventricular haemorrhage in adults. Br J Radiol 2017;90:20160779.
Naff NJ, Hanley DF, Keyl PM, Tuhrim S, Kraut M, Bederson J, et al. Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 2004;54:577–83.
van Solinge TS, Muskens IS, Kavouridis VK, Gormley WB, Mekary RA, Broekman MLD, et al. Fibrinolytics and intraventricular hemorrhage: a systematic review and meta-analysis. Neurocrit Care 2020;32:262–71.
Morgan TC, Dawson J, Spengler D, Lees KR, Aldrich C, Mishra NK, et al.; CLEAR and VISTA Investigators. The Modified Graeb Score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome. Stroke 2013;44:635–41.
Diringer MN, Edwards DF, Zazulia AR. Hydrocephalus: a previously unrecognized predictor of poor outcome from supratentorial intracerebral hemorrhage. Stroke 1998;29:1352–7.
Phan TG, Koh M, Vierkant RA, Wijdicks EF. Hydrocephalus is a determinant of early mortality in putaminal hemorrhage. Stroke 2000;31:2157–62.
Ziai WC, Nyquist PA, Hanley DF. Ventriculostomy and lytic therapy for intracerebral hemorrhage. Front Neurol Neurosci 2015;37:130–47.
Witsch J, Bruce E, Meyers E, Velazquez A, Schmidt JM, Suwatcharangkoon S, et al. Intraventricular hemorrhage expansion in patients with spontaneous intracerebral hemorrhage. Neurology 2015;84:989–94.
Witsch J, Falcone GJ, Leasure AC, Matouk C, Endres M, Sansing L, et al. Intracerebral hemorrhage with intraventricular extension associated with loss of consciousness at symptom onset. Neurocrit Care 2021;35:418–27.
You S, Zheng D, Delcourt C, Sato S, Cao Y, Zhang S, et al. Determinants of early versus delayed neurological deterioration in intracerebral hemorrhage. Stroke 2019;50:1409–14.
Torres A, Plans G, Martino J, Godino O, Garcia I, Gracia B, et al. Fibrinolytic therapy in spontaneous intraventricular haemorrhage: efficacy and safety of the treatment. Br J Neurosurg 2008;22:269–74.
Coplin WM, Vinas FC, Agris JM, Buciuc R, Michael DB, Diaz FG, et al. A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage. Stroke 1998;29:1573–9.
Huttner HB, Tognoni E, Bardutzky J, Hartmann M, Köhrmann M, Kanter I-C, et al. Influence of intraventricular fibrinolytic therapy with rt-PA on the long-term outcome of treated patients with spontaneous basal ganglia hemorrhage: a case-control study. Eur J Neurol 2008;15:342–9.
Witsch J, Roh DJ, Avadhani R, Merkler AE, Kamel H, Awad I, et al. Association between intraventricular alteplase use and parenchymal hematoma volume in patients with spontaneous intracerebral hemorrhage and intraventricular hemorrhage. JAMA Netw Open 2021;4:e2135773.
Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al.; CLEAR III Investigators. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017;389:603–11.
Hughes JD, Puffer R, Rabinstein AA. Risk factors for hydrocephalus requiring external ventricular drainage in patients with intraventricular hemorrhage. J Neurosurg 2015;123:1439–46.
Stein M, Luecke M, Preuss M, Boeker DK, Joedicke A, Oertel MF. Spontaneous intracerebral hemorrhage with ventricular extension and the grading of obstructive hydrocephalus: the prediction of outcome of a special life-threatening entity. Neurosurgery 2010;67:1243–51.
Young WB, Lee KP, Pessin MS, Kwan ES, Rand WM, Caplan LR. Prognostic significance of ventricular blood in supratentorial hemorrhage: a volumetric study. Neurology 1990;40:616–9.
Murthy SB, Awad I, Harnof S, Aldrich F, Harrigan M, Jallo J, et al.; CLEAR III Trial Investigators. Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial. Neurology 2017;89:355–62.
Kuo LT, Lu HY, Tsai JC, Tu YK. Prediction of shunt dependency after intracerebral hemorrhage and intraventricular hemorrhage. Neurocrit Care 2018;29:233–40.